The preventive phase I trial with the HIV-1 Tat-based vaccine.

Vaccine（2009）

引用 49|浏览89

暂无评分

摘要

The native HIV-1 Tat protein was chosen as vaccine candidate for phase I clinical trials based on its role in the natural infection and AIDS pathogenesis, on the association of Tat-specific immune response with the asymptomatic stage as well as on its sequence conservation among HIV clades.

查看译文

关键词

Clinical trials,HIV-1 Tat,Vaccination

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要